Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Jennifer C. Samp; Min J. Joo; Glen T. Schumock; Gregory S. Calip; A. Simon Pickard; Todd A. Lee

doi:10.1002/phar.1913

Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1002/phar.1913 ◽

2017 ◽

Vol 37 (4) ◽

pp. 447-455 ◽

Cited By ~ 8

Author(s):

Jennifer C. Samp ◽

Min J. Joo ◽

Glen T. Schumock ◽

Gregory S. Calip ◽

A. Simon Pickard ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Comparative Effectiveness ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting ◽

Beta2 Agonist

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease

Cureus ◽

10.7759/cureus.19168 ◽

2021 ◽

Author(s):

Mizuki Yuasa ◽

Yosuke Tanaka ◽

Tohru Tanaka ◽

Takeru Kashiwada ◽

Namiko Taniuchi ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012066.pub2 ◽

2017 ◽

Cited By ~ 18

Author(s):

Nobuyuki Horita ◽

Atsushi Goto ◽

Yuji Shibata ◽

Erika Ota ◽

Kentaro Nakashima ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting

Adherence To Current Guidelines For Chronic Obstructive Pulmonary Disease (COPD) In Subjects Treated With Combination Of Long-Acting Beta2-Agonist (LABA), Long-Acting Muscarinic Antagonist (LAMA) Or Inhaled Corticosteroids (ics)

10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3115 ◽

2011 ◽

Author(s):

Carl V. Asche ◽

Shelah Leader ◽

Craig Plauschinat ◽

Swetha Raparla ◽

Ming Yan ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Inhaled Corticosteroids ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting ◽

Current Guidelines ◽

Beta2 Agonist

Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease

10.1002/14651858.cd012066 ◽

2016 ◽

Cited By ~ 2

Author(s):

Nobuyuki Horita ◽

Atsushi Goto ◽

Erika Ota ◽

Kentaro Nakashima ◽

Kenjiro Nagai ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting

In people with chronic obstructive pulmonary disease, how does combination inhaled corticosteroid and long-acting beta2-agonist compare with tiotropium at improving outcomes?

Cochrane Clinical Answers ◽

10.1002/cca.26 ◽

2012 ◽

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Long Acting ◽

Beta2 Agonist

Switching from long‐acting beta‐agonist and inhaled corticosteroid to long‐acting beta‐agonist and long‐acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal

Internal Medicine Journal ◽

10.1111/imj.14931 ◽

2020 ◽

Vol 50 (S3) ◽

pp. 15-18

Author(s):

Jamie Chung Mei Lam

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Case Report ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Corticosteroid Withdrawal ◽

Long Acting

A Long-acting Muscarinic Antagonist （LAMA） Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:

The Showa University Journal of Medical Sciences ◽

10.15369/sujms.30.1 ◽

2018 ◽

Vol 30 (1) ◽

pp. 1-9

Author(s):

Koichi ANDO ◽

Akihiko TANAKA ◽

Sojiro KUSUMOTO ◽

Toshimitsu YAMAOKA ◽

Tohru OHMORI ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Beta 2 ◽

Long Acting

Inhaled Corticosteroid Plus Long-Acting Beta2-Agonist Therapy Is Overused In The Treatment Of Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year Studies

Pneumologie ◽

10.1055/s-0036-1572053 ◽

2016 ◽

Vol 70 (S 01) ◽

Author(s):

H Watz ◽

GT Ferguson ◽

L Grönke ◽

F Voss ◽

R Abrahams ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Obstructive Pulmonary Disease ◽

Long Acting ◽

Post Hoc ◽

Beta2 Agonist

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal

Applied Health Economics and Health Policy ◽

10.1007/s40258-016-0256-z ◽

2016 ◽

Vol 14 (5) ◽

pp. 579-594 ◽

Cited By ~ 7

Author(s):

M. Reza Maleki-Yazdi ◽

Mathieu Molimard ◽

Dorothy L. Keininger ◽

Jean-Bernard Gruenberger ◽

Joao Carrasco ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Cost Effectiveness ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Adrenergic Agonist ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting

How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?

Cochrane Clinical Answers ◽

10.1002/cca.1708 ◽

2017 ◽

Author(s):

Adarsh Gupta

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting